Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 6,702 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $146,639.76. Following the transaction, the chief financial officer directly owned 80,436 shares in the company, valued at $1,759,939.68. The trade was a 7.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $21.99 on Friday. The business has a 50-day moving average price of $21.10 and a 200 day moving average price of $14.13. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The firm has a market cap of $2.37 billion, a P/E ratio of -6.39 and a beta of 0.75. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same quarter last year, the firm earned ($1.00) EPS. The business’s revenue was down 45.8% on a year-over-year basis. On average, sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on RCUS. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Wedbush set a $35.00 price objective on shares of Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. The Goldman Sachs Group lifted their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.89.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high?visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy?side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short?term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after buying an additional 1,298,584 shares during the last quarter. Woodline Partners LP increased its position in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after acquiring an additional 1,603,367 shares during the period. Geode Capital Management LLC raised its stake in Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after acquiring an additional 207,097 shares in the last quarter. Bank of America Corp DE boosted its position in Arcus Biosciences by 173.5% during the 3rd quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock worth $18,507,000 after acquiring an additional 863,162 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Arcus Biosciences by 35.3% in the third quarter. Wellington Management Group LLP now owns 1,266,289 shares of the company’s stock worth $17,222,000 after purchasing an additional 330,268 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.